\
&
Contact us
\
&
Contact us
Published on | 3 years ago
Programmes HealthThe results of the evaluation are:
Boosting mental health in Europe in times of change - HORIZON-HLTH-2022-STAYHLTH-01-01-two-stage
Trustworthy artificial intelligence (AI) tools to predict the risk of chronic non-communicable diseases and/or their progression - HORIZON-HLTH-2022-STAYHLTH-01-04-two-stage
Prevention of obesity throughout the life course - HORIZON-HLTH-2022-STAYHLTH-01-05-two-stage
Source: Funding & Tenders Portal (Funding Updates)
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
